The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
|Videos|July 12, 2017
Dr. Klein on Precision Medicine for Prostate Cancer
Author(s)Eric Klein, MD
Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.
Advertisement
Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.
The prostate cancer field has entered the precision medicine era, explains Klein. There are now clinically significant tools in all the different spaces in prostate cancer, such as better screening and tests for the tumor.
Advertisement
Related to this article
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
2
Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer
3
Dr Encinas Mayoral on an AI-Designed BCMA/FcRL5-Targeting TRiTE in Multiple Myeloma
4
Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC
5